Uncategorized

ImmunoServ has been awarded Innovate UK funding as part of the Biomedical Catalyst to develop a world-first standardised T cell immunity test for Group A Streptococcus (Strep A)—a major global health threat responsible for over 600 million infections each year.

ImmunoServ are absolutely thrilled and deeply honoured to have been named the winner in the Innovation, Science & Technology category at the St David Awards 2025 – the national awards of Wales, now in their 12th year.

📣 We are proud to announce that ImmunoServ has been selected as one of three finalists for the 2025 St David Award for Innovation, Science and Technology.

ImmunoServ are delighted to be receiving a share of £1.5 million from the Infection Innovation Consortium (iiCON), a UKRI-funded initiative dedicated to tackling infectious diseases. After successful sandpit events in Liverpool and London earlier this year, iiCON announced 11 new projects during World AMR Awareness Week. These projects are focused on combating infectious diseases as part of UKRI’s ongoing work to support innovative ways of tackling infections.

We have officially moved to our new premises at the Cardiff Medicentre! 🏢🔬

ImmunoServ is pleased to announce that it has been awarded substantial follow-on funding from the Welsh Government to support its ground-breaking research and development in T cell testing.

🚀 ImmunoServ are excited to announce the launch of our TCR Sequencing Service powered by iRepertoire’s technology! 🧬✨

As part of our ongoing efforts to bring T cell testing to the masses, today ImmunoServ are proud to announce the launch of the COVID-19 Immuno-T™ Laboratory Test Kit. Having generated substantial impact during the COVID-19 pandemic with our contract T cell and antibody research services, the launch of the Immuno-T™ Laboratory Test Kit now enables standardised and scalable T cell testing to be performed in any laboratory throughout the world.

The UK is currently in the midst of another wave of COVID-19, causing increases in hospitalisation rates [1]. Whilst the UK Health Security Agency do not believe the newly emerged and currently circulating SARS-CoV-2-Omicron subvariants to be any more dangerous than previous strains, experts have attributed the current wave to both increased indoor mixing and waning immunity [2]. But what data do we have to show that population immunity is in fact waning?

Funding to expand ImmunoServ’s portfolio of services for monitoring cellular immune responses.